Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Tiziana Expects To Start Enrolling Patients in Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using its Novel Intranasal Monoclonal Antibody Foralumab

--News Direct--

By Rachael Green, Benzinga

This month, Tiziana Life Sciences (NASDAQ: TLSA) expects to start enrolling patients for a phase 2a trial of Foralumab, an immunomodulation therapy for Secondary Progressive Multiple Sclerosis (SPMS) that’s administered through the nose. The news marks a major milestone on the path to bring the clinical-stage company’s lead drug candidate to market.

MS Patients Have Few Effective Treatment Options, And SPMS Patients Have Even Fewer

The incurable disease involves recurring painful flare-ups that can be so severe people lose the ability to walk or move. This happens when the immune system attacks parts of the body’s own central nervous system, damaging nerve fibers and interrupting communication between the brain and the rest of the body.

The oral medications that are available are generally immune-suppressing drugs that can reduce relapse rates. But because they are typically a blanket suppressant of the immune system, they also generally come with harmful side effects and increased risk of infection. Moreover, they aren’t always effective for patients with non-active secondary progressive MS (SPMS), the more severe and difficult-to-treat form of the disease that Tiziana is developing Foralumab for.

When a flare-up strikes, the current standard of care for MS generally involves either intravenous corticosteroids for reducing inflammation or blood plasma exchange – both of which need to be done in a hospital.

Positive 6-Month Clinical Results Give Hope That Foralumab Could Make A Difference In Patients’ Lives

Foralumab is an anti-CD3 monoclonal antibody. It binds to the CD3 receptor on the surface of T cells in the patient’s immune system. Rather than a blanket immune suppressor, this mechanism of action selectively dampens the autoimmune response — when the T cells attack the body’s own cells — without disrupting its ability to detect and fight external pathogens.

This has made it a promising candidate for fighting autoimmune diseases like MS as it has the potential to prevent painful autoimmune attacks without the severe side effects and risks that come with other immune-suppressing drugs.

Tiziana reports that Foralumab is the only anti-CD3 monoclonal antibody therapy currently in development that is fully human, meaning it's even less likely to trigger adverse reactions than the genetically engineered versions being developed by other pharmaceutical companies.

In October, the biopharma reported that five of the six patients who received the intranasal treatment in its expanded access program showed reduced microglia activation, a key biomarker of immune response and a possible contributing factor to the damaging flare-ups MS patients experience.

Positron Emission Tomography (PET) scans of the patients at three months and six months both found decreased microglia activity in the brain. That six-month clinical data also showed improvement across a number of other measures of the disease.

“Notably, in this latest clinical update for patients EA 3 through EA 6, we have seen improvement in the Modified Fatigue Impact Scale scores in three out of four patients, which is significant since fatigue is a major complaint in this population,” said Principal Investigator and Professor of Neurology at Harvard Medical School, Dr. Tanuja Chitnis, M.D.

“We have also seen various degrees of improvement in the Expanded Disability Status Scale, Timed 25-Foot Walk Test, pyramidal function scores and NeuroQoL Fatigue scores in a disease state that typically shows a decline in function over time.“

Building on that positive data, Tiziana is getting ready for a new phase 2a study of the intranasal treatment.

“I believe that the six-month qualitative na-SPMS PET readout by Dr. Singhal is very encouraging and will enable us to rapidly advance foralumab in Phase 2a testing to address patients afflicted with this devastating disease who currently have no FDA-approved treatments available,” said Tiziana Founder Gabriele Cerrone.

Patient enrollment for the new trial is expected to begin in December 2023.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Benzinga

+1 877-440-9464

info@benzinga.com

Company Website

http://www.benzinga.com

View source version on newsdirect.com: https://newsdirect.com/news/tiziana-expects-to-start-enrolling-patients-in-its-phase-2-clinical-trial-to-treat-secondary-progressive-multiple-sclerosis-spms-using-its-novel-intranasal-monoclonal-antibody-foralumab-208851552

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.